Skip to main content

Table 2 Serum Ceramides (nmol/L) of individuals among the three groups

From: Ceramide d18:1/24:1 as a potential biomarker to differentiate obesity subtypes with unfavorable health outcomes

 

NW

OB

 
 

NC (n = 21)

MHO (n = 20)

MUO (n = 36)

P

Cer d18:0/18:0

245.1 (132.4,349.6)

105.2 (90.3,217.9)a

152.8 (108.7,265.3)

0.015

Cer d18:0/24:1

165.9 (116.8,352.7)

135.5 (87.5,225.4)

131.4 (95.0,223.0)

0.308

Cer d18:1/16:0

740.9 (649.9,994.9)

559.2 (462.5,710.3)a

616.1 (545.4,829.2)

0.028

Cer d18:1/18:0

451.4 (223.4,559.3)

284.8 (232.1,380.0)

328.6 (233.8,458.3)

0.531

Cer d18:1/20:0

247.0 (114.6,394.4)

209.4 (158.5,250.3)

250.7 (158.6,452.0)

0.25

Cer d18:1/22:0

785.5 (519.9,981.2)

895.6 (753.0,1240.0)

1147.5 (824.3,1464.1)a

0.003

Cer d18:1/24:1

1600.1 (1013.9,2078.8)

1582.3 (1310.7,1969.0)

2201.4 (1676.2,2923.4)ab

＜0.001

Cer d18:1/24:0

2123.8 (1700.9,3391.0)

2680.4 (2048.0,3895.3)

3287.5 (2396.1,4505.9)a

0.025

Cer

7181.1 (5121.9,7926.6)

6326.1 (5563.2,8312.3)

8271.9 (6784.7,10703.3)ab

0.009

  1. The concentration values of ceramides were transformed into a normal distribution by logarithm
  2. The concentrations of ceramides among the three groups were compared via one-way ANOVA with Bonferroni correction
  3. Continuous variables that were not normally distributed were presented as median (quartile1, quartile3)
  4. a Significant differences (P < 0.05) were shown with the NC group through post hoc tests. b Significant differences (P < 0.05) were shown with MHO through post hoc tests
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X